Reneo Pharma appoints Gregory Flesher to its Board as CEO and announces $95m Series B financing co-led by Novo Ventures and Abingworth

– USA, CA –  Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases, today announced it raised $95 million in a Series B financing co-led by Novo Ventures and Abingworth and supported by existing investors New Enterprise Associates, RiverVest Venture Partners, Pappas Capital, and Lundbeckfonden Ventures, as well as new investors Rock Springs Capital, Aisling Capital, Amzak Health, and other investors.…

Lava Therapeutics adds Dr Nanna Lüneborg, Dr Laia Crespo and Joël Jean-Mairet to Board along with raising $83m Series C financing co-led by Novo Ventures and Sanofi Ventures

– NETHERLANDS, Utrecht –  LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 million Series C financing co-led by new investors Novo Ventures, the venture arm of Novo Holdings, and Sanofi Ventures, and included additional new investors Redmile Group, LLC, Ysios Capital and BB Pureos Bioventures.…